The first joint meeting between the Emirates Cardiac Society and the American College of Cardiology formed the basis of the growing incidence of heart diseases, which is ranked as the number one cause of death in the Gulf States.
Recent studies show that more than half of the population in the Gulf states suffers from abnormal cholesterol levels, a quarter has high blood pressure and 15 -25 per cent have diabetes. These numbers coupled with a rapid increase in the rate of obesity adds up to alarming statistics.
The joint meeting hosted several distinguished doctors from the region and from the American College of Cardiology who delivered a series of informative lectures about various aspects of cardiovascular health.
The meeting began with the AstraZeneca Satellite Symposium. The topics discussed the “CEPHEUS” research project and the future of cardiovascular disease prevention.
“CEPHEUS” is a large research program involving 5,300 patients across the Gulf who are currently treated for high cholesterol levels. The project was launched last November by the Emirates Cardiac Society in collaboration with AstraZeneca, an Anglo/Swedish biopharmaceutical company, which was also the part sponsor of the joint meeting. The main aim of this project is to monitor the percentage of patients who reach their cholesterol level treatment goal while taking cholesterol lowering medications.
“We are keen to facilitate joint initiatives between professional organizations and believe that exchange of knowledge is key to improving the quality of cardiac care,” said Tarek Rabah, President of AstraZeneca Gulf.
Dr. Anthony N. DeMaria, Editor-in-Chief of the Journal of the American College of Cardiology stressed on the increasing burden of heart diseases worldwide. “In India, more people are dying from atherosclerosis of heart disease than of infectious diseases,” he pointed out.
There were also sessions on cardiac infarction and treatment, cholesterol management guidelines and general cardiology conducted as part of the meeting.